Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
02 October 2020Website:
http://www.lensar.comNext earnings report:
04 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 22 Nov 2024 21:00:02 GMTDividend
Analysts recommendations
Institutional Ownership
LNSR Latest News
LENSAR, Inc. (NASDAQ:LNSR ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning, and thank you for participation. At this time, all participants are in a listen-only mode.
ORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 650 shares of the Company's common stock. The options were granted as of November 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that more than one million procedures have been performed using its technology.
ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company's common stock. The options were granted as of October 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
LENSAR, Inc. (NASDAQ:LNSR ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Cameron Radinovic - IR Nicholas Curtis - CEO & Director Thomas Staab - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ryan Zimmerman - BTIG Operator Good morning and thank you for your participation. [Operator Instructions].
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,150 shares of the Company's common stock. The options were granted as of June 3, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listi.
LENSAR, Inc. (NASDAQ:LNSR ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Good morning, and thank you for your participation. [Operator Instructions] As a reminder, this conference call is being recorded.
LENSAR, Inc. (NASDAQ:LNSR ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Cameron Radinovic – Burns McClellan Nick Curtis – Chief Executive Officer Tom Staab – Chief Financial Officer Conference Call Participants Ryan Zimmerman – BTIG Operator Good morning and thank you for your participation. At this time all participants are in a listen-only mode.
What type of business is LENSAR?
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
What sector is LENSAR in?
LENSAR is in the Healthcare sector
What industry is LENSAR in?
LENSAR is in the Medical Devices industry
What country is LENSAR from?
LENSAR is headquartered in United States
When did LENSAR go public?
LENSAR initial public offering (IPO) was on 02 October 2020
What is LENSAR website?
https://www.lensar.com
Is LENSAR in the S&P 500?
No, LENSAR is not included in the S&P 500 index
Is LENSAR in the NASDAQ 100?
No, LENSAR is not included in the NASDAQ 100 index
Is LENSAR in the Dow Jones?
No, LENSAR is not included in the Dow Jones index
When was LENSAR the previous earnings report?
No data
When does LENSAR earnings report?
The next expected earnings date for LENSAR is 04 March 2025